. Author manuscript; available in PMC: 2014 Feb 1.

Published in final edited form as: Cancer Treat Rev. 2012 Aug 13;39(1):97–104. doi: 10.1016/j.ctrv.2012.07.002

Table 3.

Characteristics of Study Participants

Demographics	Denosumab (N=3,191)	Bisphosphonates (N=2,951)
Mean age (years)	62.2	62.3
ECOG 0-1	2,837	2,617
ECOG 2	303	312
Prior SRE	1,168	1,109
Presence of visceral metastases	1,187	1,154

ECOG, European Cooperative Oncology Group SRE, skeletal-related event